Evaxion announce 2027 financial calendar
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
Evaxion A/S Submits Amendment To Its Registration Statement On Form F-1 Regarding 2025 Debt Settlement Agreement With The European Investment Bank With SEC
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
Evaxion Announces Data From Its Phase 2 Study Of EVX- In Participants With Advanced Melanoma Demonstrates Induced Immune Responses, Underlines Predictive Performance
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
Evaxion To Demonstrate New Data For EVX-04 Vaccine At American Society Of Hematology Annual Meeting
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma - Slideshow
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript
EVAX Stock Heads For Best Week Since January 2025 As Cancer Vaccine Shows 89% Target Precision
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Evaxion Reports All Patients Maintained Clinical Response With No Tumor Progression Through Year Three Of EVX-01 Monotherapy In Advanced Melanoma Phase 2 Trial, 89% Of Vaccine Neoantigens Triggered T-Cell Responses
Evaxion stock surges on 3-year melanoma vaccine trial data
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ...
Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.